natgillin/translations-raw huggingface dataset:
When non-weight adjusted dosing was administered, it was found after a single-subcutaneous 40 mg dose, that anti-Xa exposure is 50% higher in low-weight women ( &lt; 45 kg) and 27% higher in low-weight men ( &lt; 57 kg) when compared to normal weight control subjects (see section 4.4).
Kada se primjenjuju doze koje nisu prilagođene prema težini, nakon jednokratne supkutane primjene doze od 40 mg, izloženost anti-Xa je 50% veća u žena niske tjelesne težine ( &lt; 45 kg) i 27% veća u muškaraca niske tjelesne težine ( &lt; 57 kg) u usporedbi s ispitanicima normalne tjelesne težine iz kontrolne skupine (vidjeti dio 4.4).
When NovoSeven is administered to patients outside approved indications, arterial thromboembolic events are common (≥ 1/100 to &lt; 1/10).
Kada se NovoSeven primjenjuje u bolesnika izvan odobrenih indikacija, arterijske tromboembolije su česte (≥ 1/100 i &lt; 1/10).
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated patients as memantine-treated patients showed worsening in all three domains (21% vs.
Kada je ustanovljeno istodobno pogoršanje stanja bolesnika u sva tri područja rezultati su pokazali statistički značajan učinak memantina u sprječavanju pogoršanja, u skupini bolesnika liječenih placebom bilo je dvostruko više pogoršanja u sva tri područja nego u skupini bolesnika liječenih memantinom (21% naspram 11%, p &lt; 0,0001).
When patients were identified with concurrent worsening in all three domains, results showed a statistically significant effect of memantine in preventing worsening, as twice as many placebo-treated patients as memantine-treated patients showed worsening in all three domains (21% vs.
Kada je ustanovljeno istodobno pogoršanje stanja bolesnika u sva tri područja, rezultati su pokazali statistički značajan učinak memantina u sprječavanju pogoršanja, u skupini bolesnika liječenih placebom bilo je dvostruko više pogoršanja u sva tri područja nego u skupini bolesnika liječenih memantinom (21% naspram 11%, p &lt; 0,0001).
When platelet count &gt; 100 x 103/ μl resume RoActemra at 4 mg/kg and increase to 8 mg/kg as clinically appropriate
Kad broj trombocita naraste na &gt; 100 x 103/ μl, nastaviti s primjenom lijeka RoActemra u dozi od 4 mg/kg te povećavati dozu na 8 mg/kg, prema kliničkoj potrebi
When platelet count &gt; 100 x 103/ μl resume RoActemra dosing every other week and increase to every week injection as clinically appropriate.
Kad broj trombocita naraste na &gt; 100 x 103/ μl, nastaviti s primjenom lijeka RoActemra jedanput svaka dva tjedna, a zatim povećati učestalost na jedanput tjedno, prema kliničkoj potrebi.
When platelet count is &gt; 100 x 103/l resume RoActemra
Kada se broj trombocita poveća na &gt; 100 x 103/μl, nastaviti primjenu lijeka RoActemra.
When platelet count is &gt; 100 x 103/l resume RoActemra
Kada se broj trombocita poveća na &gt; 100x103/μl, nastaviti primjenu lijeka RoActemra
When Sovaldi is used in combination with ribavirin or peginterferon alfa/ribavirin, refer also to the Summary of Product Characteristics for ribavirin for patients with creatinine clearance (CrCl) &lt; 50 mL/min (see also section 5.2).
Kad se Sovaldi primjenjuje u kombinaciji s ribavirinom ili peginterferonom alfa / ribavirinom, pročitajte također Sažetak opisa svojstava lijeka za ribavirin za bolesnike s klirensom kreatinina (CrCl) &lt; 50 ml/min (vidjeti također dio 5.2).
When stratified by weight, a lower (30-40%) median of exposure for Cmin,ss (11.4 vs 19 µg/ml) and AUCss (594 vs 880 µg*d/ml) for the lower bodyweight category (≤ 40 kg) vs the higher bodyweight category ( &gt; 40 kg) was observed.
Kada se stratificira prema težini, uočen je niži (30-40%) medijan izloženosti za Cmin,ss (11,4 naspram 19 µg/ml) i AUCss (594 naspram 880 µg*d/ml) za nižu kategoriju tjelesne težine (≤ 40 kg) u usporedbi s višom kategorijom tjelesne težine ( &gt; 40 kg).
When the efficacy of enoxaparin and unfractionated heparin were compared, the rate of the primary efficacy endpoint, including death or myocardial re-infarction in the first 30 days after randomisation, was 9.9% in the enoxaparin group, as compared to 12.0% in the unfractionated heparin group, that is a 17% reduction in the relative risk (p &lt; 0.001).
Kada se uspoređuju djelotvornost enoksaparina i nefrakcioniranog heparina, stopa mjera primarnog ishoda djelotvornosti, uključujući smrt ili reinfarkt miokarda unutar prvih 30 dana nakon randomizacije, iznosila je 9,9 % u skupini koja je primala enoksaparin, u usporedbi s 12 % u skupini koja je primala nefrakcionirani heparin, što znači smanjenje relativnog rizika za 17 % (p &lt; 0,001).
When the efficacy of enoxaparin and unfractionated heparin were compared, the rate of the primary efficacy endpoint, including death or myocardial re-infarction in the first 30 days after randomisation, was 9.9% in the enoxaparin group, as compared to 12.0% in the unfractionated heparin group, that is a 17% reduction in the relative risk (p &lt; 0.001).
Kada se uspoređuju djelotvornost enoksaparina i nefrakcioniranog heparina, stopa mjera primarnog ishoda djelotvornosti, uključujući smrt ili reinfarkt miokarda unutar prvih 30 dana nakon randomizacije, iznosila je 9,9% u skupini koja je primala enoksaparin, u usporedbi s 12% u skupini koja je primala nefrakcionirani heparin, što znači smanjenje relativnog rizika za 17% (p &lt; 0,001).
When the efficacy of enoxaparin and unfractionated heparin were compared, the rate of the primary efficacy endpoint, including death or myocardial re-infarction in the first 30 days after randomisation, was 9.9% in the enoxaparin group, as compared to 12.0% in the unfractionated heparin group, that is a 17% reduction in the relative risk (p &lt; 0.001).
Kada se uspoređuju djelotvornost enoksaparina i nefrakcioniranog heparina, stopa mjera primarnog ishoda djelotvornosti,, uključujući smrt ili reinfarkt miokarda unutar prvih 30 dana nakon randomizacije, iznosila je 9,9% u skupini koja je primala enoksaparin, u usporedbi s 12% u skupini koja je primala nefrakcionirani heparin, što znači smanjenje relativnog rizika za 17% (p &lt; 0,001).
When the value zero is included, i.e. when the lower limit of the CI is &lt; 0, the efficacy is not considered statistically significant.
Kada je uključena nulta vrijednost, odnosno kada je donja granica CI &lt; 0, djelotvornost se ne smatra statistički značajnom.
When using a higher threshold for eosinophilia ( &gt; 1.4 x 109/l), the patient exposure adjusted rate of eosinophilia is equal in both groups (1.8 patients with event per 100 patient- years).
Ako se primijeni viši prag za eozinofiliju ( &gt; 1,4 x 109/l), tada je stopa eozinofilije prilagođena u odnosu na izloženost bolesnika jednaka u obje skupine (1,8 bolesnika s nuspojavom na 100 bolesnik-godina).
Whenever cardiomyopathy is suspected, i.e., the left ventricular ejection fraction has substantially decreased relative to pre-treatment values and/or left ventricular ejection fraction is lower than a prognostically relevant value (e.g., &lt; 45%), endomyocardial biopsy may be considered and the benefit of continued therapy must be carefully evaluated against the risk of developing irreversible cardiac damage.
U slučaju sumnje na kardiomiopatiju, npr. kad je ejekcijska frakcija lijeve klijetke znatno smanjena u odnosu na vrijednosti prije liječenja i/ili je niža od prognostički važne vrijednosti (npr., &lt; 45%), moguće je razmotriti biopsiju endomiokarda, a korist od nastavka liječenja mora se pažljivo procijeniti u odnosu na rizik od razvoja ireverzibilnog srčanog oštećenja.
Whereas an estimated 96% (93%) of patients with CCyR (PCyR) at 12 months were free of progression to accelerated phase/blast crisis at 84 months, only 81% of patients without MCyR at 12 months were free of progression to advanced CML at 84 months (p &lt; 0.001 overall, p=0.25 between CCyR and PCyR).
Dok je otprilike 96% bolesnika s CCyR-om, odnosno 93% bolesnika s PCyR- om nakon 12 mjeseci bilo bez progresije u ubrzanu fazu/blastičnu krizu nakon 84 mjeseca, samo je 81% bolesnika bez MCyR nakon 12 mjeseci bilo bez progresije u uznapredovali KML nakon 84 mjeseca (p &lt; 0,001 ukupno, p=0,25 između CCyR-a i PCyR-a).
While taking orlistat, the patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately 30% of calories from fat (e.g. in a 2,000 kcal/day diet, this equates to &lt; 67 g of fat).
Za vrijeme uzimanja orlistata osoba mora biti na nutricijski uravnoteženoj, blago hipokaloričnoj dijeti u kojoj oko 30% kalorija potječe od masti (npr. u dijeti s 2000 kcal/dan, to odgovara količini &lt; 67g masti).
While they may in reality occur at lower frequencies than indicated below, the size of the source database did not allow for the assignment of frequency categories lower than the category “uncommon” (≥1/1,000 to &lt; 1/100).
Iako se u stvarnosti mogu javiti rjeđe nego što je ovdje navedeno, veličina izvorne baze podataka nije omogućila svrstavanje nuspojava u kategoriju učestalosti manju od “manje često” (≥1/1000 i &lt; 1/100).
While they may in reality occur at lower frequencies than indicated below, the size of the source database did not allow for the assignment of frequency categories lower than the category “uncommon” (≥1/1,000 to &lt; 1/100).
Iako se u stvarnosti mogu javiti rjeđe nego što je ovdje navedeno, veličina polazišne baze podataka nije omogućila svrstavanje nuspojava u kategoriju učestalosti manju od “manje često” (≥1/1000 i &lt; 1/100).
Whole blood elimination half-life is prolonged ( &gt; 100 days) in humans due to RBC carbonic anhydrase binding.
Poluvijek eliminacije iz kompletne krvi je produljen ( &gt; 100 dana) kod ljudi zbog vezivanja karboanhidraze u eritrocitima.
Widespread use of a 2-dose vaccination schedule in the United States and countries such as Finland and Sweden has led to a &gt; 99% reduction in the incidence of each of the 3 targeted diseases.
Široka primjena dvije doze prema kalendaru cijepljenja u Sjedinjenim Američkim Državama i zemljama poput Finske i Švedske dovela je do &gt; 99% smanjenja incidencije svake od te 3 ciljne bolesti.
Widespread use of a 2-dose vaccination schedule in the United States and countries such as Finland and Sweden has led to a &gt; 99% reduction in the incidence of each of the 3 targeted diseases.
Široko primjenjivan raspored cijepljenja s 2 doze u Sjedinjenim Američkim Državama i zemljama poput Finske i Švedske doveo je do smanjenja incidencije svake od te 3 ciljne bolesti za &gt; 99%.
with a propensity to bleed (e.g. due to recent trauma, recent surgery, recent or recurrent gastrointestinal bleeding, or active peptic ulcer disease) with body weight &lt; 60 kg (see sections 4.2 and 4.8).
koji su skloni krvarenju (npr. zbog nedavne traume, nedavnog kirurškog zahvata, nedavnog ili opetovanog gastrointestinalnog krvarenja ili aktivnog peptičnog ulkusa) tjelesne težine &lt; 60 kg (vidjeti dijelove 4.2 i 4.8).
With baseline CD4+ cell
S početnim brojem CD4+ stanica &lt; 200
With Herceptin subcutaneous formulation, concentrations were approximately at steady-state following Cycle 7 dose (pre-dose Cycle 8) with small increase in concentration ( &lt; 15%) up to Cycle 13.
Kod primjene lijeka Herceptin u supkutanoj formulaciji, koncentracije su približno postigle stanje dinamičke ravnoteže nakon primjene doze u 7. ciklusu (prije primjene doze u 8. ciklusu), uz malo povećanje koncentracije ( &lt; 15%) do 13. ciklusa.
With increasing renal impairment, from mild (CLcr 50 to &lt; 80 ml/min) to moderate (CLcr 30 to &lt; 50 ml/min) to severe renal impairment (CLcr &lt; 30 ml/min), the fraction of regadenoson excreted unchanged in urine and the renal clearance decreased, resulting in increased elimination half- lives and AUC values compared to healthy subjects (CLcr ml/min).
Pogoršanjem bubrežne funkcije, od blage (CLcr 50 do &lt; 80 ml/min) do umjerene (CLcr 30 do &lt; 50 ml/min) i do teške (CLcr &lt; 30 ml/min), udio regadenosona koji se izlučuje nepromijenjen urinom i klirens bubrega su opadali, imajući za posljedicu porast poluživota eliminacije i vrijednosti AUC, u usporedbi sa zdravim ispitanicima (CLcr ml/min).
With respect to the primary efficacy endpoint, the proportion (%) of patients achieving HIV RNA &lt; 50 copies/ml at Week 48 was 241/280 (86.1 %) in the group receiving ISENTRESS and 230/281 (81.9 %) in the group receiving efavirenz.
Što se tiče primarnog ishoda djelotvornosti, udio (%) bolesnika u kojih je u 48. tjednu postignuta koncentracija &lt; 50 HIV-RNK kopija/ml iznosio je 241/280 (86,1%) u skupini koja je primala ISENTRESS i 230/281 (81,9%) u skupini koja je primala efavirenz.
With Trulicity 1.5 mg, a significantly higher percentage of patients reached a target HbA1c of &lt; 7.0 % and ≤ 6.5 % at 24 weeks compared to placebo.
Ciljnu vrijednost HbA1c od &lt; 7,0% i ≤ 6,5% u 24. tjednu postigao je značajno veći postotak bolesnika liječenih lijekom Trulicity 1,5 mg nego onih koji su primali placebo.
Withdrawal due to nausea or vomiting each occurred in &lt; 1 % for prolong-release exenatide treated patients and 1 % for immediate-release exenatide treated patients.
Do prekida liječenja zbog mučnine došlo je, jednako kao i zbog povraćanja, u &lt; 1% bolesnika liječenih eksenatidom s produljenim oslobađanjem te u 1% bolesnika liječenih eksenatidom s trenutnim oslobađanjem.
Withdrawal due to nausea or vomiting each occurred in &lt; 1 % for prolonged-release exenatide treated patients and 1 % for immediate-release exenatide treated patients.
Do prekida liječenja zbog mučnine došlo je, jednako kao i zbog povraćanja, u &lt; 1% bolesnika liječenih eksenatidom s produljenim oslobađanjem te u 1% bolesnika liječenih eksenatidom s trenutnim oslobađanjem.
Withhold Iclusig and resume at 15 mg after recovery to
Obustavite primjenu lijeka Iclusig i nastavite s dozom od 15 mg nakon oporavka na &lt; stupanj 2
Withhold Iclusig and resume at 30 mg after recovery to
Obustavite primjenu lijeka Iclusig i nastavite s dozom od 30 mg nakon oporavka na &lt; stupanj 2
Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness, using the following convention: Very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Unutar svake skupine po učestalosti nuspojave su navedene slijedom prema sve manjoj ozbiljnosti, prema sljedećem dogovoru: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common ( &gt; 1/10); common ( &gt; 1/100 to &lt; 1/10); uncommon ( &gt; 1/1000 to &lt; 1/100); rare ( &gt; 1/10,000 to &lt; 1/1,000): not known (cannot be estimated from the available data).
Unutar svake skupine prema učestalosti, nuspojave su navedene padajućim slijedom prema njihovoj ozbiljnosti: vrlo često ( &gt; 1/10); često ( &gt; 1/100 i &lt; 1/10); manje često ( &gt; 1/1000 i &lt; 1/100); rijetko ( &gt; 1/10,000 i &lt; 1/1000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common ( &gt; 1/10); common ( &gt; 1/100 to &lt; 1/10); uncommon ( &gt; 1/1000 to &lt; 1/100); rare ( &gt; 1/10,000 to &lt; 1/1,000); not known (cannot be estimated from the available data).
Unutar svake skupine prema učestalosti, nuspojave su navedene padajućim slijedom prema njihovoj ozbiljnosti: vrlo često ( &gt; 1/10); često ( &gt; 1/100 i &lt; 1/10); manje često ( &gt; 1/1000 i &lt; 1/100); rijetko ( &gt; 1/10,000 i &lt; 1/1,000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1000 to &lt; 1/100) and not known (cannot be estimated from the available data).
Unutar svake grupe učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1000 to &lt; 1/100) and not known (cannot be estimated from the available data).
Unutar svake grupe učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100) i nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each System Organ Class, adverse reactions are listed under frequency categories of very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Unutar svake klasifikacije organskih sustava nuspojave su navedene prema kategoriji učestalosti kao vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Within each system organ class, adverse reactions are listed under headings of frequency using the categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); not known (cannot be estimated from the available data).
Unutar svakog organskog sustava, nuspojave su navedene prema sljedećim kategorijama učestalosti pojavljivanja: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the designated system organ classes, the adverse drug reactions are listed under headings of frequency and using the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Unutar svakog organskog sustava nuspojave su razvrstane prema učestalosti pojavljivanja prema sljedećoj konvenciji: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Unutar klasifikacije organskih sustava nuspojave su navedene prema i učestalosti (broj bolesnika u kojih se očekuje pojava navedene reakcije), sukladno sljedećim kategorijama: vrlo često ( ≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Unutar klasifikacije organskih sustava nuspojave su navedene prema učestalosti (broj bolesnika u kojih se očekuje pojava navedene reakcije) sukladno sljedećim kategorijama: vrlo često ( ≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Unutar klasifikacije organskih sustava nuspojave su navedene prema učestalosti (broj bolesnika u kojih se očekuje pojava navedene reakcije), sukladno sljedećim kategorijama: vrlo često ( ≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Unutar klasifikacije organskih sustava nuspojave su navedene prema učestalosti (broj bolesnika u kojih se očekuje pojava navedene reakcije), sukladno sljedećim kategorijama: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10), and uncommon (≥ 1/1,000 to &lt; 1/100).
Nuspojave su razvrstane prema organskim sustavima i kategorijama učestalosti definiranima na sljedeći način: često (≥ 1/10), često (≥ 1/100 i &lt; 1/10) i manje često (≥ 1/1000 i &lt; 1/100).
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Unutar organskih sustava, nuspojave su navedene prema sljedećim kategorijama učestalosti pojavljivanja: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko ≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known.
Nuspojave su razvrstane prema organskim sustavima i kategorijama učestalosti definiranima na sljedeći način: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato.
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known.
Nuspojave su razvrstane prema organskim sustavima i kategorijama učestalosti definiranima na sljedeći način: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato.
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100, &lt; 1/10).
Nuspojave su razvrstane prema organskim sustavima i učestalosti pojavljivanja definiranoj kao vrlo često (≥ 1/10), često (≥ 1/100, &lt; 1/10).